Comparison of the MyoMed-946 and MyoMed-205 proteome data sets suggests that MyoMed-946-treated EDL may contain higher levels of Ttll12 (tubulin-tyrosine ligase-like protein 12) and Tbc1d17, both regulators of tubulin dynamics [47,48], correlating in ovarian cancers with a poor outcome [49]. Here, TTLL12 is linked to ovarian carcinoma.